Why the IPF Summit?
The IPF field feels undoubtedly exciting and companies seem to be moving swiftly through clinical trials!
However, understanding lung pathobiology to explore the early vs late drivers of pulmonary fibrosis, using valuable preclinical models for IND-enabling and to cement translational confidence, whether to harness imaging as a secondary, exploratory endpoint throughout therapeutic development, patient selection and patient recruitment, are some of the questions running through the IPF minds and are at the centre of every conversation.
Therefore, it is vital for the community to come together in 2024 to further:
Explore emerging biological understanding of the drivers of pulmonary fibrosis including epithelial, endothelial, macrophages, fibroblasts, myofibroblasts, understand the vasculature to highlight targets and pathways for drug discovery
Harness novel, dynamic, preclinical models including precision cut lung slices, organoids, novel animal models, to cement translational confidence beyond bleomycin for your IPF therapeutic
Capture imaging and AI for biomarkers and endpoints for IPF to have greater insight into therapeutic efficacy beyond lung function
Work to effectively recruit and design trials that are reflective of the pulmonary fibrosis patient population
Look to novel therapies including gene therapy, mRNA, cell therapies, oligonucleotides and more
Don’t miss out on the conversations the IPF community will be having next August 2024, be in the conversations to overcome the challenges and advance the next generation of IPF drugs.
"The IPF Summit, time and again, proves its value to investigators, academicians, and drug developers alike for the insights it generates and the networking it affords”
Senior Lead – Clinical Program & Interstitial Lung Disease , Boehringer Ingelheim
"A great opportunity to discuss advances and opportunities in clinical and translational science in the interest of advancing care for patients with IPF”
Head of Biomarker Discovery , AstraZeneca
"Being part of the conversation for developing novel IPF therapies”
Chief Medical Officer ,Pliant Therapeutics
"Connecting with colleagues and learning about new science and clinical development related to lung fibrosis”
Executive Medical Director, Early Clinical Development & Experimental Sciences, , Regeneron Pharmaceuticals
"Provide valuable insight into biomarker development and implementation in patients with IPF”
Clinical Associate Professor , University of Michigan
"Opportunity to learn from diverse attendees ranging from basic scientist, academic physicians, seasoned clinical trialists, and industry experts. A comprehensive range of topics will be covered that span exciting advances in knowledge on the pathogenesis of IPF, novel in vitro and in vivo models of pulmonary fibrosis, novel endpoints to accelerate development of clinical trials, and optimal recruitment strategies to deliver clinical studies”
Executive Director – Early Clinical Development, Respiratory & Immunology , AstraZeneca
"I’ve thoroughly enjoyed attending the IPF Summit - a conference for innovators – it’s a premier event for therapeutic advancements in a fatal lung disease”
Chief Medical Officer , Vicore Pharma
In the 2023 Agenda
Attendees heard phase 2 and 3 clinical trial updates from Bristol Myers Squibb, Pliant Therapeutics, Galecto, and Vicore Pharma and took away key lessons , while benchmarking their drug development to bring more efficacious therapeutics to patients faster.
About the Emerging Biology & Early Translational Track:
|Determine the importance of epithelial and endothelial cells, explore repair, regeneration, and clearing senescent cells to understand the pathobiology of pulmonary fibrosis with National Jewish Health, Genentech, and Boehringer Ingelheim
|Illuminate early-stage biomarkers for patient selection and identification for therapeutic development with Gatehouse Bio, Astrazeneca, and Pfizer
|Explore novel, dynamic preclinical models to use in combination with the bleomycin model to create a compelling IND-enabling package and have translational confidence in your IPF pipeline with Genentech, Oxcia and Pieris Pharmaceuticals
|Understand cell cross talk using genomics, proteomics and RNA sequencing with Naftali Kaminski
|Understanding the functional consequences of genetic abnormalities for pulmonary fibrosis and the opportunity to use genetics as a superior predictive tool with Gisli Jenkins and Harvard Medical School
About the Late Translational
and Clinical Track:
|Harness imaging and use AI as endpoints in clinical trials to measure biomarkers beyond lung function with Toby Maher, Boehringer Ingelheim, and Imperial College London
|Capture interstitial lung abnormalities (ILAs) to illuminate early-stage disease and progression of pulmonary fibrosis with Harvard Medical School and Boehringer Ingelheim
|Explore using innovative biomarkers in therapeutic development for a precision medicine approach in pulmonary fibrosis with AstraZeneca, Pfizer, and University of Michigan
|Assess clinical trial designs from patient selection of early- vs late-stage vs those on the standard of care, 12 week vs 52 week studies, decentralized trials, and more to design swifter and efficacious trials with Toby Maher, AstraZeneca, Vicore, Pulmonary Fibrosis Foundation and Gilead
|Deliberate combination considerations to look ahead as multiple therapeutics are expected to hit the market to debate sequential therapies including MoA, modelling, administration, and trial design with AbbVie and Gilead
Who Did You Meet?
180+ senior decision makers from C-Level executives to senior scientists from the leading pulmonary fibrosis biopharma companies will unite in Boston with the KOL academics including Toby Maher, Fernando Martinez, Naftali Kaminski, Gisli Jenkins, and many more. Individuals across the whole teams of discovery science, research, translational, biomarker, clinical, regulatory, and patient recruitment colleagues united in one room to advance efficacious pulmonary fibrosis therapeutics forward to patients.